Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FBP1 | P09467 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | AURKA | O14965 | 1/20 | 0.43 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | KLK3 | P07288 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | EIF4A1 | P60842 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6080679 | 0.83 | TSHR (0.49) | FBP1TSHRMEN1KMT2AALDH1A1 | |
| SCHEMBL6080463 | 0.80 | TSHR (0.46) | TSHRMEN1KMT2AAURKAAURKB | |
| SCHEMBL6079388 | 0.79 | PARP1 (0.41) | TSHRALDH1A1TDP1 | |
| SCHEMBL28197872 | 0.79 | KMT2A (0.53) | FBP1MEN1KMT2AAURKAAURKB | |
| SCHEMBL13313369 | 0.77 | MEN1 (0.60) | FBP1MEN1KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL6081016 | 0.77 | PDE10A (0.56) | TSHRMEN1KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL6079333 | 0.76 | CRHBP (0.52) | FBP1TSHRSMN1; SMN2TDP1MAPK1 | |
| SCHEMBL6080761 | 0.75 | MAPT (0.47) | TSHRMEN1KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL4954968 | 0.75 | MAPT (0.55) | TSHRALDH1A1SMN1; SMN2 | |
| SCHEMBL6080203 | 0.74 | TSHR (0.40) | TSHRAURKAAURKBALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060183909-A1 | Compositions derived from quinoline and quinoxaline, preparation and use thereof | NEURO3D (FR) | 2006-08-17 | — | — | US | claimed |
| US-20060183909-A1 | Compositions derived from quinoline and quinoxaline, preparation and use thereof | NEURO3D (FR) | 2006-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060183909-A1 | Compositions derived from quinoline and quinoxaline, preparation and use thereof | NQO1, NQO2, RECQL | FBP1 1265/4885TSHR 4728/4885MEN1 740/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.